Circulating non-coding RNAs as potential diagnostic biomarkers in liver diseases

Fedra Mokhtari1, Seyed Reza Mohebbi2, Afsaneh Sharifian2, Marzieh Ramandi3, Mohammad Reza Razzaghi4

1 Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3 Proteomics Research Center, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4 Laser Application in Medical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT
The liver plays a principal role in the human body as a metabolic and detoxifying unit. Liver diseases are the world’s major health problems and affect millions of people worldwide. Early detection of liver diseases is certainly effective in timely treatment and prevention of their progression. Liver injury is associated with significant alterations in immune responses and pattern changes in various tissue-related gene expressions and cytokine production. Increasing or decreasing the specific spectrum of non-coding RNAs in different phases of liver disease can be a criterion for diagnosis. Novel diagnostic biomarkers are needed for liver diseases. Currently, micro-RNAs (miRNAs) are known to play important roles in the diagnosis of liver diseases. Circulating biomarkers such as miRNA-assisted diagnosis can conceivably be helpful for the early treatment of liver diseases. In this review, we look at miRNAs and their potential applications in liver diseases as diagnostic biomarkers were investigated.

Keywords: Non-coding RNAs, microRNAs, Circulating biomarkers, Liver diseases, Viral hepatitis, Chronic disease.

Introduction
Liver diseases are common causes of mortality in the world and comprise different types such as hepatitis A, B, C and D (acute and chronic), cirrhosis, autoimmune related liver diseases including autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), primary sclerosing cholangitis (PSC), nonalcoholic fatty liver (NAFLD), nonalcoholic steatohepatitis (NASH), alcoholic steatohepatitis (ASH), and hepatocellular carcinoma (HCC). Liver damage occurs in different stages (Fig. 1). Miscellaneous factors can injure the liver, including viral infections, toxins, hereditary conditions, or autoimmune processes; however, the main etiologies include viral infections, alcohol consumption, and exposure to high levels of some toxic chemicals.
Clinical data shows that there are up to 400 million HBV surface antigen carriers worldwide (1), and about 180 million people are infected with the hepatitis C virus (HCV) (2). Approximately 170,000 deaths due to liver cirrhosis occur annually in Europe (3). Moreover, evidence indicates liver cirrhosis-related mortality has escalated during recent years. In the United States, it has been estimated that between 0.15% in 1998 to 0.27% in 2010 (1) of people deal with NAFLD (4). Distinct types of liver diseases in different stages place a heavy economic and psychological burden on governments and societies, and therefore, the precise identification and diagnosis of diseases at different stages are very important. MicroRNA (miRNA) is a small-sized non-coding RNA that binds to the target
mRNA, resulting in mRNA degradation or translation inhibition. miRNAs play important roles in regulating cell growth, proliferation, and metabolism. Circulating miRNAs have been studied as a candidate for diagnosis of a variety of diseases, such as malignancies and cardiovascular, neurologic, or metabolic diseases, including diabetes, NAFLD, and other liver diseases (2).

**Liver disease in the Middle East**

Liver and gastrointestinal diseases are also major causes of health problems and deaths in the Middle East (6, 7), with liver cirrhosis being one of the top four causes of mortality in the Middle East. However, there is a significant heterogeneity in the pattern, incidence, mortality, and burden of gastrointestinal and liver diseases in the region. Infectious diseases causing gastrointestinal (GI) and liver diseases still remain highly important in countries like Pakistan and Afghanistan; on the other hand, a clear shift from contagious to non-communicable GI diseases is noticeable in countries with a more structured healthcare system and higher economical levels. Pakistan has experienced a significant rate of cirrhosis. Mortality caused by cirrhosis in Egypt has also been significantly high, followed by other regional countries including Afghanistan, Yemen, and Morocco. Chronic liver diseases are very prevalent in Iraq with the most important causes being hepatitis B, hepatitis C, immune hepatitis, and metabolic diseases, in rank order. Non-alcoholic fatty liver disease has shown an increasing rate, and non-alcoholic steatohepatitis became a leading indication for liver transplantation in this country. In Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, Oman, Jordan, and Iraq, cases of GI cancers are increasing, and chronic hepatitis B and C are the main causes of liver cirrhosis and progression to hepatocellular carcinoma (8-11). Around 25% of the global adult population, ranging from 13.5% in Africa to 31.8% in the Middle East, experience NAFLD complications (3). Additionally, the worldwide burden of HCC mortality is anticipated to hit one million deaths annually by 2030 (12-14).

In Iran, the consequences of cancers of the stomach and esophagus are significantly greater than other countries. The Global Burden of Disease (GBD) study showed that almost 5400 deaths due to chronic liver diseases such as cirrhosis occurred in Iran in 2017 (12, 13). In accordance with the recent GBD record from Iran, the

---

*Figure 1. Etiologies and natural history and progression of chronic liver diseases. HBV: Hepatitis B virus, HCV: Hepatitis C virus, NAFLD: nonalcoholic fatty liver disease, NASH: nonalcoholic steatohepatitis, HCC: hepatocellular carcinoma*
A large cohort study has confirmed HLA alleles have shown that HLA systems play important roles in the prevalence of different liver diseases in a population. Other factors, mainly those related to the host, may link to susceptibility to liver diseases, including HCV or HBV chronic infections. For example, genetic variations such as single nucleotide polymorphism in cytokine genes are probably associated with susceptibility to HCV or HBV chronic diseases (24-27).

Liver diseases

Viral hepatitis
Hepatitis A, B, D, E, and occasionally hepatitis C infections may cause acute diseases of the liver. Hepatitis A virus (HAV) is a small RNA virus belonging to the Picornaviridae family that only leads to an acute hepatitis. It is transmitted through the fecal-oral route, while the hepatitis B virus (HBV) is transmitted parenterally (from mother to child) as well as sexually (28). HBV is a DNA virus and a member of the Hepadnaviridae family that is unique in its genomic characterization among human viruses, antigenic structure, and replication cycle (29). In addition to acute hepatitis, HBV can also lead to chronic liver disease. The hepatitis C virus (HCV) is a member of the Flaviviridae family and a blood-borne RNA virus (30). The hepatitis E virus (HEV) is also a small RNA virus that belongs to the Hepeviridea family and mainly causes acute hepatitis; however, chronic infections have been reported in patients with immune deficiency and transplant recipients (31, 32). HBV and HCV chronic infections can progress to liver cirrhosis in as many as 25% of cases and to hepatocellular carcinoma (HCC) in a significant proportion of infected patients (33). The hepatitis delta virus (HDV) is a small subviral particle with RNA genome. It can only infect HBV carriers. Hepatitis D tends to be a fierce disease, with an intense desire to lead to cirrhosis (34).

Autoimmune liver diseases
When the body’s immune system attacks the liver, autoimmune complications of the liver will occur. Nevertheless, with regard to grade of intensity and clinical course, these diseases can have different clinical patterns and outcomes. The most prominent autoimmune liver diseases (AILDs) can refer to autoimmune hepatitis (AIH), primary biliary cirrhosis (PBC), and primary sclerosing cholangitis (PSC). The target of the immune system in AIH is hepatocytes, and this consequently lead to chronic inflammation of the liver (34-36). In PBC, the autoimmune reactions are directed at small biliary ducts inside the liver. In primary sclerosing cholangitis, uncontrolled autoimmune responses target the larger extrahepatic bile ducts (37, 38). Several classes of autoantibodies are related to autoimmune liver diseases, such as AMA, ANA, anti-LKM, anti-SMA/anti-F-actin, and others. For AIH and PBC, detecting these autoantibodies is an effective prerequisite for diagnosis, but not for PBS, because their diagnostic value has not been well established. In spite of all that, diagnosis at an early stage can lead to hepatitis being controlled by proper treatments for suppressing inflammation; these treatments, however, are just for controlling and not curing. Genetic factors are strongly associated with the pathogenesis of AILDs. For example, like other autoimmune diseases, HLA loci is involved in the development of AIH and PBC (39, 40). A large cohort study has confirmed HLA-DRB1*0301 as a primary susceptibility genotype and HLA-DRB1*0401 as a secondary susceptibility genotype for AIH (41). Other alleles such as HLADRB1*0405, HLADRB1*0404, HLADRB1*07 and HLADRB1*13 alleles have been reported to increase the risk of developing AIH. Some studies have shown that HLADRB1*0803, HLADRB1*0801, HLADRB1*14, and HLADPB1*0301I are associated with PBC risk (42-47).
According to studies, some non-HLA genes are susceptible to AIH, including CARD10, STAT4, SH2B3, CTLA-4, and TNFA. Moreover, other non-HLA genes responsible in signaling pathways can be considered as allelic risk factors of PBC, such as IL-12 production and antigen presenting process (e.g., IRF5, NF-kB, TNFAIP3, NF-kB, SOCS1, and IL-12A), T cell stimulating and secretion of IFN-γ (e.g., IL12R, TNFSF15, TYK2, TNFAIP3, and STAT4). In PBS, several susceptibility genes may play a role in bile acid homeostasis, such as HDAC7 and TGR5, and T cell-related risk loci (e.g., CTLA4/CD28, MMELi/TNFRSF14, CD226, PRKD2, IL2/IL21, and CCL20) is associated with disease progression. Immune homeostasis may be disrupted by regulating immune tolerance, cytokine production, and immune responses due to dysfunctional gene products (48-51). However, the details of AILD development mechanisms remain unclear, while researchers have focused on epigenetic processes and microRNAs functions (52).

**NAFLD/NASH**

Nonalcoholic fatty liver has become a common cause of chronic liver disease. It is a range of conditions, from steatosis to nonalcoholic steatohepatitis (NASH), that can progress to fibrosis, cirrhosis, and hepatocellular carcinoma. The global prevalence of NAFLD is estimated at approximately 24%, with considerable variability from Africa (13.5%) to South America (30.5%), the Middle East (31.8%), and other regions of Asia (33.9%). Some factors can be considered causes for NAFLD, such as obesity, type 2 diabetes mellitus (T2DM), insulin resistance, and possibly iron metabolism problems. Leite et al. studied 180 T2DM patients and observed that 69%, 54%, and 28% of these patients also suffered from NAFLD, NASH, and liver fibrosis grade 2 or higher, respectively (53-59). Diabetes can aggravate NAFLD and lead to more severe forms of steatohepatitis, fibrosis, and even HCC. NAFLD itself can also modify the natural history of T2DM (60). Finally, in patients with T2DM, the presence of NAFLD is associated with an increased risk of overall death. Moreover, it is an independent predictor of death together with the presence of ischemic heart disease and duration of diabetes. The effects of NAFLD expand beyond the liver, and it is associated with a range of chronic diseases, especially cardiovascular disease (CVD), diabetes mellitus type 2 (T2DM), and chronic kidney disease (CKD). Fatty liver disease caused primarily by persistent excessive alcohol consumption is known as alcoholic liver disease (ALD). Differentiating between ALD and NAFLD is difficult, as it relies on patient-reported consumption (61). As obesity is common, risk factors for NAFLD may be present in individuals who also consume high levels of alcohol (62, 63).

NASH is the progressive form of NAFLD (64). NASH may happen because of fat aggregation in the liver followed by hepatocellular ballooning, liver cell inflammation, and injury (steatohepatitis). NASH symptoms mainly consist of non-specific disease manifestations such as fatigue, abdominal pain, lethargy, and sleeping problems; thus, they may sometimes be falsely interpreted (65). Most people live with the disease for years unaware of the damage accumulating in their liver, because NASH is, typically, only detected when it has progressed to cirrhosis or liver cancer (66). NASH is defined as a series of necroinflammatory processes, whereby the liver cells become injured in a background of steatosis. The largest study to date to analyze the prevalence of NAFLD and fibrosis due to NASH was performed in a group of young, largely asymptomatic Caucasians with suspected NAFLD in the UK. The results revealed that one in five of the studied subjects had steatosis, and one in 40 showed evidence of fibrosis due to NASH at only 24 years of age (67). An increased risk of NAFLD and NASH at a younger age may progress and lead to serious health complications in early adulthood (68). People with NASH have an overall mortality rate of 7.9% within seven years of diagnosis (69).

**Cirrhosis and hepatocellular carcinoma**

Cirrhosis is the end phase of chronic liver disease, and fibrosis is the stage prior to cirrhosis (70). Many types of molecules such as miRNAs and cytokines are associated with the start and advancement of liver fibrosis and, therefore, cirrhosis (71). Stimulation of hepatic stellate cells (HSCs) is a pivotal event in the fibrosis of hepatocytes and probably contributes to the pathogenesis of cirrhosis (72). Stimulated Kupffer cells can damage hepatocytes and activate HSCs (73). Repeated courses of hepatocyte death and regeneration of these cells contribute to the pathogenesis of liver cirrhosis. In addition, several cytokines play crucial roles in HSC stimulation and activation of fibrogenesis (74, 75). Hepatitis B and C infections and obesity are other risk factors for cirrhosis (76). The majority of hepatocellular carcinoma cases...
S14  Non-coding RNAs as potential diagnostic biomarkers in liver diseases

Occur after liver cirrhosis; however, cirrhosis itself may happen as a result of an infection, exposure to toxins, immunopathological/autoimmune/allergic reactions, a vascular process, or an inborn metabolism error (77).

**Hepatocellular carcinoma**

Hepatocellular carcinoma (HCC) is the fifth most prevalent cancer in men in the world, and the interaction between the two factors of environment and genetics can probably facilitate HCC development (78). Viruses like HBV and HCV, in addition to NASH, NAFLD, and ingestion of aflatoxin B1 and alcohol, are risk factors for HCC development (Fig. 1) (79, 80). HCC is often associated with liver cirrhosis, which is an outcome of progressive chronic liver diseases by HBV or HCV infection, chronic hepatitis, or autoimmune hepatitis (81). Early diagnosis has led to first-stage treatment and has also significantly increased the survival rate of patients (82-84). Hepatitis B virus infection is the most common cause of HCC in the world and in Iran (85). HBV is more prevalent in some regions of the world such as Asia (86, 87). Patients who suffer chronic HBV infection for a longer duration and/or have less accessibility to diagnostic facilities and prompt anti-viral therapies are at a higher risk for HCC (88). Reports have revealed that infection with HCV is responsible for an increase in the number of cases of HCC among US veterans (89). Additionally, occult HBV or HCV infections, obesity, insulin resistance syndrome, and diabetes should be considered as probable risk factors for HCC in the world today (90). Diabetes and obesity indirectly increase the hazard of HCC by increasing the risk of NAFLD and cirrhosis. The process of inflammatory cascade might be induced because of insulin resistance (91).

**Diagnosis and preventing of liver diseases**

Liver complications may progress to end-stage liver diseases, such as cirrhosis and/or HCC (92). End-stage complications can be prevented by widespread and precise screening and prompt treatment for chronic liver diseases. Screening for chronic liver disease can be accomplished with the measurement of transaminase concentrations, ultrasonography, and some invasive methods (93). However, using noninvasive methods to screen for liver diseases is more favorable. Liver diseases can be verified by liver biopsy, but this examination is invasive and may not be routinely accomplished (94). Serum liver enzymes such as alkaline phosphatase (ALP), alanine aminotransferase (ALT), Gamma-glutamyl transferase (GGT), and aspartate aminotransferase (AST) can be routinely tested (95). ALP and GGT evaluation might reveal cholestatic complications, while increased levels of ALT and AST might imply the possibility of hepatocellular injuries (96). Albumin and bilirubin are also two important liver function biochemical markers. Bilirubin can specifically increase during liver disease, but the sensitivity of the bilirubin test is not high enough and bilirubin level escalation often occurs in late phases of liver diseases (97). Albumin is used to evaluate the liver’s biosynthetic activity and capability, and the hepatic synthesis of albumin will decrease in end-stage liver diseases (98). Albumin serum levels might drop in cases with disorders like malabsorption, nephrotic syndrome, or protein-losing enteropathy or even malnutrition. Serum ALT activity is the most commonly utilized biochemical marker for liver injury; however, much clinical research has demonstrated that ALT levels do not always correlate well with liver histopathological changes, and ALT activities may be altered in other clinical disorders, such as polymyosistis or skeletal muscle injury. Consequently, the need for more specific and authentic markers of liver injury continues to exist (99).

**MiRNAs in liver diseases**

MicroRNAs (miRNA) are small regulatory and noncoding RNAs that play an essential role in balancing cellular gene expression at post-transcriptional levels (100). MiRNAs can modulate gene expression in a variety of biological process such as proliferation, apoptosis, and differentiation (101). MiRNAs also can regulate viral replication and pathogenesis in a number of different ways which include facilitation, activation of immune responses, epigenetic modulation, and several other effects (102). They bind to the target messenger RNAs (mRNA) and regulate gene expression, so possibly resulting in the inhibition of translation or reduction in the stability of the mRNA, both of which can cause decreased expression of a target protein (103). Each miRNA can control and modulate several genes, and most mRNA targets contain multiple miRNA binding sites (104). Variations in the sequence of a mature miRNA can result in the elimination or changes in binding affinity to target miRNAs. In addition, mutations in target mRNAs are a possible mechanism that may lead to altered expression in some diseases (105). MicroRNAs have been considered a promising candidate for the next generation of noninvasive, diagnostic biomarkers because of the strong correlation between
microRNA expression patterns and the progression of several diseases (106). Most miRNA sequences are usually conserved among that species, and some miRNA expression is tissue-specific or highly specific to distinct biological or developmental phases (107). One of the main miRNAs in the liver is miR-122, the expression of which might be dysregulated in HBV and HCV chronic infections. Recent findings have indicated that the miR-122 levels may be linked to the severity of these diseases. The relative quantification of miRNA levels can be easily performed using the real time qPCR technique, which utilizes precise signal amplification (108). Therefore, miRNA quantification can be considered a sensitive, specific, robust, and noninvasive method for assessing disease progression (109). There are several serious challenges facing the effective employment of miRNAs as circulating biomarkers, including inadequate standardized methods which may lead to bias in results interpretation (110). Sample gathering and storage variations, appropriate and effective nucleic acid extraction, miRNA quality and quantity examination, and all other pre-amplification steps are important, technically challenging factors. Variability is another problem which makes difficult the cross comparison of studies published from different laboratories. Three platforms are used for miRNA quantification: microarrays, quantitative real-time PCR, and next-generation sequencing (NGS) (111). Some miRNAs can be deregulated in multiple disorders and in different cancers (112). Some studies have suggested that miRNA can regulate host genes (113). Overall, according to the miRNA potential and based on what has been said, they can be used to determine the susceptibility to developing a disease, measure its progress, or predict prognosis (114).

Some studies have been done on different miRNAs. Hui Zhang et al. worked on three groups: chronic hepatitis B (CHB) patients, healthy controls, and patients with NASH. They compared the expression levels of 34 miRNAs between these groups. Their results showed that the median levels of miR-122, -572, -575, and -638 were significantly higher while miR-744 was significantly lower in CHB compared with the controls. The levels of miR-122, -572, and -638 were also higher, while the level of miR-744 was lower in CHB than in NASH, although the difference between them was not as significant as that between CHB and controls. Further analysis revealed a probable correlation between these miRNA expression levels and liver function parameters. Serum levels of miR-122, -572, -575, -638, and -744 are deregulated in patients with CHB or NASH, and as a final conclusion, the levels of these miRNAs can serve as potential biomarkers for liver disease caused by NASH and CHB (115). Gui et al. performed miRNAs profiling from HCC/liver cirrhosis patients’ serum pools using qPCR-based TaqMan MicroRNA quantification arrays in comparison with healthy controls. They checked five miRNAs: miR-885-5p, miR-574-3p, miR-224, miR-215, and miR-146a, and found higher levels of miR-885-5p in sera from patients with HCC, liver cirrhosis, and CHB (116). A wide number of studies have shown that HBV infection modulates levels of different host miRNAs, but only a few reports have established the exact role of viral proteins in these modulations. Hepatitis B x protein (HBx) plays a particular role in the regulation of host miRNAs among all viral proteins. Wang et al. found that HBx transcript had significant effects on miR-15a/miR-16-1 suppression, even in the absence of HBx protein. This result confirmed the principal role of the HBx in the modulation of miRNA levels. In addition, the association of HBx protein with miR-29a up-regulation, which in turn enhances cell migration by targeting PTEN in hepatoma cell lines, was determined. DNA methyl transferase3A is also targeted by HBx, ensuring high DNA methylation and managing miR-101 down-regulation. Wang et al. showed that HBx transcript can mediate the repression of miR-15a/miR-16-1 directly, without the essential necessity of HBx protein, thus denoting the vital role of the HBx gene in host miRNA regulation (117). Furthermore, Wang et al. showed that the let-7 family miRNAs (including let-7a, let-7b, and let-7c) which control MYC, Ras, HMG2, and STAT3 expression, can be targeted by HBx, resulting in the modulation of host oncogenesis and immune response. This study revealed that significant changes in various host miRNAs may happen in HBx expressing cells (118). Another research showed that HBx protein can modulate the expression of tumor suppressor miR-145 and oncomiRs miR-21 and miR-222 in malignant hepatocytes differentially (119). In addition, during chronic hepatitis B progression, miRNA-146a can be up-regulated by HBx protein, and the complement factor H might be down-regulated (120). A profile analysis of miRNAs consisting of miR-122, miR-638, miR-575, and miR-572 was proposed by Zhang et al. with a considerable diagnostic potential for CHB (121). Another study by Zhang et al.
conducted in 2015, demonstrated that expression levels of four miRNAs (miR-134, miR-122, miR-629-5p, and miR-424-3p) were up-regulated during HCV infection (122). Another study reported the dysregulation of 106 out of 768 miRNAs in the serum of HCV-infected patients and it further demonstrated that expression levels of four miRNAs (miR-134, miR-134, miR-424-3p, and miR-629-5p) were up-regulated during HCV infection (123). It is assumed that miRNAs that have a role in lipid metabolism and homeostasis possibly participate in the pathogenesis of NAFLD and other metabolic disorders; thus, the evaluation of such role can be helpful for disease diagnosis (124). Moreover, miR-122, miR-34a, and miR-16 serum levels were significantly higher in NAFLD patients than in healthy control groups. The miR-122 and miR-34a levels were also closely linked to disease intensity of NASH (125). The miR-192, miR-21, and miR-122 were found to be significantly overexpressed in NAFLD and NASH patients compared to healthy individuals. In addition, miR-192 and miR-122 were also able to discriminate NAFLD from NASH (126). Interestingly, the down-regulated expression of miR-122 could diagnose NASH from simple steatosis differentially (127). Another study demonstrated that serum levels of miR-122 were positively correlated with the intensity of NASH (128). Previous studies have revealed that miRNAs contribute to the activation of hepatic stellate cells (HSCs) and proliferation, thus regulating the progression of liver fibrosis. Particularly, the miR-29 family has emerged as a key regulator of liver fibrosis (129). Another study showed the potential of miR-200b and miR-122 in human patients for initial diagnosis of liver fibrosis (130). Some studies have indicated that miR-122 can play a principal role in controlling cancer cell proliferation, mutagenesis, and vascular invasion; therefore, it can be regarded as a tumor suppressor (131). Another research showed that the levels of miR-224 and miR-122 in plasma can be helpful in the early diagnosis of hepatocellular carcinoma in humans (132). Some studies have reported miR-221, miR-21, and miR-222 up-regulation and miR-145, miR-122a, miR-199a, and miR-223 down-regulation in HCC in comparison with normal human tissue (133, 134). Some miRNAs have been particularly reported as biomarkers for hepatocellular carcinoma, including miR-214, miR-199a-3p, miR-199a-5p, miR-125a-5p, miR-195, miR-139-5p, miRNA-1269, miR-139-3p, miR-224-3p, miR-497, miR-424-3p, miR-452, and miR-130a. Chen et al. demonstrated the relationship between miR-221 and HCC and its potential as a diagnostic marker for HCC. Furthermore, they suggested that HCC patients with up-regulated miRNA-221 expression had a shorter survival time (135).

A 2019 study by Zhou et al. demonstrated that circulating miR-122 has an important diagnostic significance for the detection of chronic viral hepatitis (136). Ping Xu et al. compared miR-122, miR-125b, and miR-192 with a conventional marker ALT in 326 serum samples and demonstrated enhanced levels of MiR-125b in HCV patients. In this study, miR-122 and miR-192 were linked to liver injuries by chemicals; however, a major increase was observed in serum miR-122 in patients with active HBV. Interestingly, in alcohol-associated liver injuries, a major increase in these miRNAs could not be observed. Thus, the evaluation of both miR-122 and miR-125b as prognostic biomarkers of liver injury might be helpful (137). In a 2019 survey, Ghaempoor et al. proposed that miR-625 may be considered as a potential noninvasive biomarker for the diagnosis of liver cirrhosis (138). In 2021, Kim et al. examined and evaluated miR-21-5p, miR-192-5p, miR-151a-3p, and miR-4449 as biomarkers for progression to NASH in NAFLD patients (5). Fründt et al. showed in their 2021 study that exosomes secreted into the plasma differentially expressed miRNAs. Moreover, miR-146, miR-192, and miR-16 are prognostic and diagnostic markers for both HCC and liver cirrhosis (139). Ashrafi et al. found that the tissue levels of hsa-miR-3158-5p, -194-5p, -4449, and -548as-3p were correlated to progression to HCC (140). It was also shown that miRs including miR-122-5p, miR-187-3p, miR-193a-5p, and miR-378d were linked to hepatic steatosis in research by Zhang et al. In addition, miR-122-5p, miR-193a-5p, and miR-193b-3p were strongly correlated to liver fibrosis and can be used as biomarkers of fatty liver disease (Table 1) (141).

**MiRNAs in other diseases**

Whether in liver-related diseases or in other complications including cancers, neurological and autoimmune diseases, miRNAs play significant roles through molecular pathways of complex biological processes, such as regulating cell death, proliferation, and differentiation. For example, in cancer, miRNA expression patterns change at different stages of cancer progression. Some cancer-related miRNAs, including miR-16, miR-15, and let-7, were considered as tumor suppressors; however, other miRNAs such as miR-155 and miR-21 may function as...
Table 1. A list of the microRNAs and their changes associated with various liver diseases and clinical conditions.

| Liver disease                      | Involved miRNAs                                                                 | Expression   | Ref          |
|------------------------------------|---------------------------------------------------------------------------------|--------------|--------------|
| HCV infection                      | • miR-122, miR-134, miR-122, miR-424-3p, miR-629-5p, miR-125b                   | Up           | (98), (111), (125) |
| Chronic hepatitis B (CHB)           | • miR-29a, miR-15a/miR-16-1, let-7a, let-7b, let-7c, miR-122, miR-572, miR-575, miR-638, miR-885-5p, miR-145, miR-21, miR-222, miRNA-146a, miR-744, miR-101 | Deregulate   | (89) , (98), (105), (106), (107), (108), (109), (110), (12) |
| Nonalcoholic steatohepatitis (NASH) | • miR-122, miR-572, miR-575, miR-638, miR-192, miR-21, miR-744                | Up           | (105), (113), (116) |
| Nonalcoholic fatty liver (NAFLD)    | • miR-122, miR-34a, miR-16, miR-192, miR-21                                    | Deregulate   | (12), (123) |
| Fibrosis                           | • miR-29, miR-200b, miR-122, miR-193a-5p, miR-193b-3p, miR-885-5p, miR-146, miR-192 and miR-196, miR-192 and miR-16 | Down         | (117), (118) |
| Cirrhosis                          | • miR-885-5p, miR-146, miR-192 and miR-16                                        | -Deregulate  | (106), (126) |
| Hepatocellular carcinoma (HCC)     | • miR-885-5p, miR-221, miR-21, miR-222                                            | Up           | (106), (119), (120), (126) |
| Autoimmune hepatitis (AIH)         | • miR-145 miR-122a, miR-199a,miR-223                                              | Down         | (127) |
| Primary biliary cirrhosis (PBC)     | • miR-21, miR-122, miR-10a, miR-133a, miR-210                                     | Up           | (139), (140), (141) |
| Primary sclerosing cholangitis (PSC)| • miR-1281, miR-126, miR-200c, miR-122                                             | Down         | (142-145) |

oncogenes (142, 143). MiR-16 and MiR-15 cause cell death in cancerous cells by suppressing the expression of anti-apoptotic gene bcl-2 and let-7 family members, demonstrate anti-cancer properties by suppressing oncogene expression, RAS (144, 145). MiR-155 inhibits MSH gene family expressions in CRC and prevents mismatch repair processes. MiR-21 directly serves as an anti-apoptotic determinant in breast cancer and glioblastomas (146). Some studies have elucidated the miRNA functions in neurodegenerative diseases (ND) such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). It seems that because of the very high expression of BACE1 protein, which plays an important role in the pathogenesis of AD, a decrease in the expression levels of miR-9, miR-29a, and miR-29b-1 occurs (147). In Parkinson’s disease, leucine-rich repeat kinase 2 (LRRK2) also promote the expression of transcriptional factors E2F1 by downregulating the expression of miR-184 and let-7 (148). MiRNAs also play critical roles in inflammation by controlling the nuclear factor kappa beta (NF-KB) related pathways, a key factor in inflammatory responses. Several different surveys have implied that miRNAs perform leading roles in various diseases related to the immune system, such as systemic lupus erythematosus (SLE), multiple sclerosis (MS), type I/II diabetes, and also NAFLD. Studies have also shown the up-regulation of miR-155, miR-34a, and miR-326 in MS lesions, decreasing expression of miR-146a in SLA patients, increased expression of miR-200a, miR-200b, and miR-429 and decreased expression of miR-27, miR-122, and miR-451 in diet-induced NAFLD in experimental animal models (149, 150). One study demonstrated that miR-107 and miR-103 negatively regulate insulin sensitivity and glucose homeostasis in type 2 diabetes by targeting caveolin-1, a tight regulator of insulin receptors (151). In viral infections,
viruses are capable of regulating the expression of host cellular miRNAs for their own benefit, although the expression of some cellular miRNAs is not directly controlled by viruses. Nonetheless, maintenance of their intracellular levels is pivotal for some viral infections and replication (For example, high levels of liver-specific miR-122 expression is necessary for HCV replication). The increasing levels of miR-155 in HCV patients revealed that up-regulation of miR-155 may activate the Wnt signaling pathway and contribute in part to HCV-induced hepatocarcinogenesis (152-163). To summarize, in addition to host genetic mutations (164, 165) or pathogens’ genetic variations (166-171) that effect some liver diseases progression and clinical status, microRNAs are important molecular players and worth further investigations.

Conclusions
So far, many studies have been performed on the association of miRNAs with various complications, including liver diseases. The stability, sensitivity, and specificity of miRNA expression in tissues and blood circulation make miRNAs potential biomarkers for the diagnosis and prognosis of several diseases, including viral hepatitis and other liver diseases. The relationship between pattern changes in many miRNA levels under different clinical and pathological conditions have been extensively studied. However, there is still a long way to go before miRNAs can reach the clinic as reliable and definitive diagnostic markers. The serum profiling of miRNAs in infectious and non-infectious liver diseases may be introduced as a non-invasive, accurate, and at the same time holistic approach in medical practice in the future.

Acknowledgment
The authors would like to acknowledge the support from the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences.

Conflict of interests
The authors declare that they have no conflict of interest.

References
1. Lee WM. Hepatitis B virus infection. N Engl J Med 1997;337:1733-45.
2. Blach S, Zeuzem S, Manns M, Altraif I, Duberg AS, Muljono DH, et al. Polaris observatory HCV collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2017;2:161-76.
3. Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol 2013;58:593-608.
4. Caussy C, Soni M, Cui J, Bettencourt R, Schork N, Chen CH, et al. Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis. J Clin Invest 2017;127:2697-2704.
5. Kim TH, Lee Y, Lee YS, Gim JA, Ko E, Yim SY, et al. circulating miRNA is a useful diagnostic biomarker for nonalcoholic steatohepatitis in nonalcoholic fatty liver disease. Sci Rep 2021;11:14639.
6. Sepanlou SG, Malekzadeh F, Delavari F, Naghavi M, Forouzanfar MH, Moradi-Lakeh M, et al. Burden of gastrointestinal and liver diseases in Middle East and North Africa: results of global burden of diseases study from 1990 to 2010. Middle East J Dig Dis 2015;7:201-15.
7. Golabi P, Paik JM, AlQahtani S, Younossi Y, Tuncer G, Younossi ZM. Burden of Nonalcoholic Fatty Liver Disease in Asia, Middle East and North Africa: Data from Global Burden of Disease 2009-2019. J Hepatol 2021;75:795-809.
8. Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Iran: an overview. 2015. Gastroenterol Hepatol Bed Bench 2015;8:19-27.
9. Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation. Transplantation 2019;103:22-27.
10. European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
11. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411-428.
12. Pourhoseingholi MA, Fazeli Z, Ashtari S, Bavyand-Pour FS. Mortality trends of gastrointestinal cancers in Iranian population. Gastroenterol Hepatol Bed Bench 2013;6:552-7.
13. Anushiravani A, Ghajarieh Sepanlou S. Burden of Liver Diseases: A Review from Iran. Middle East J Dig Dis 2019;11:189-191.
14. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019;16:411-428.
15. Malekzadeh F, Sepanlou SG, Poustchi H, Naghavi M, Forouzanfar MH, Shahraz S, et al. Burden of gastrointestinal and liver diseases in Iran: estimates based on the global burden of disease, injuries, and risk factors study. Middle East J Dig Dis 2015;7:138-54.
16. Shirifian A, Ashtari S, Hatami B, Mohebbi SR, Naderi N. Risk factors of transmission and natural history of chronic hepatitis B infection in Iranian patients. Gastroenterol Hepatol Bed Bench 2019;12:S149-155.
17. Salehi-Vaziri M, Sadeghi F, Almasi Hashiani A, Gholami Fesharaki M, Alavian SM. Hepatitis B Virus Infection in the
General Population of Iran: An Updated Systematic Review and Meta-Analysis. Hepat Mon 2016. 16(4): p. e35577.

18. Mohaghegh Shalmani H, Noori A, Shokoohi M, Khajavi A, Darvishi M, Delavari A, et al. Burden of Hepatitis C in Iran Between 1990 and 2010: findings from the Global Burden of Disease Study 2010. Arch Iran Med 2015 Aug;18(8):508-14.

19. Hajarizadeh B, Razavi-Shearer D, Merat S, Alavian SM, Malekzadeh R, Razavi H. Liver disease burden of hepatitis C virus infection in Iran and the potential impact of various treatment strategies on the disease burden. Hepat Mon 2016;16:e37234.

20. Ostovaneh MR, Zamani F, Ansari-Moghaddam A, Sharafkhah M, Saeedian FS, Rohani Z, et al. Nonalcoholic fatty liver: the association with metabolic abnormalities, body mass index and central obesity—a population-based study. Metab Syndr Relat Disord 2015;13:304-11.

21. Hatami B, Ashtari S, Sharifian A, Rahmani Seraji H, Khalili E, et al., Changing the cause of liver cirrhosis from hepatitis B virus to fatty liver in Iranian patients. Gastroenterol Hepatol Bed Bench 2017;10:S20-S26.

22. Modares Mousavi SR, Geramizadeh B, Anushiravanani A, Ejtehadi F, Anbarchard MH, Moini M. Correlation between Serum Ferritin Level and Histopathological Disease Severity in Non-alcoholic Fatty Liver Disease. Middle East J Dig Dis 2018;10:90-95.

23. Moghaddasifar I, Lankarani KB, Moosazadeh M, Afshari M, Ghaemi A, Alfiramezn M, et al. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Int J Organ Transplant Med 2016;7:149-160.

24. Baradaran Ghavami S, Mohabibi SR, Karimi K, Azimzadeh P, Sharifian A, Mojahed Yazdi H, et al., Variants in two gene members of the TNF ligand superfamily and hepatitis C virus chronic disease. Gastroenterol Hepatol Bed Bench 2018;11:S66-S72.

25. Tayefinasraddabi H, Mohabibi SR, Hosseini SM, Azimzadeh P, Pourhoseingholi MA, Ghaemi A, et al. Association of Interleukin-17 gene polymorphisms with susceptibility to chronic hepatitis B virus infection and clearance in Iranian population. Microb Pathog 2020;144:104195.

26. Shoraka S, Mohabibi SR, Hosseini SM, Hosseini Razavi A, Hatami Y, Sharifian A, et al. Association between Interleukin-21 and Interleukin-21 receptor gene polymorphisms with susceptibility to chronic hepatitis B virus infection and HBV spontaneous clearance in Iranian population. Microb Pathog 2019;128:263-267.

27. Karkhane M, Mohabibi SR, Azimzadeh P, Avarandeh H, Kazemian S, Sharifian A, et al. Genetic association between a single nucleotide polymorphism in Interleukin-16 (rs4072111) and susceptibility to chronic HCV infection in an Iranian population. Gastroenterol Hepatol Bed Bench 2018;11:42-47.

28. Gilson R and Brook MG. Hepatitis A, B, and C. Sex Transm Infect. 2006;82 Suppl 4(Suppl 4):iv35-9.

29. Liang TJ. Hepatitis B: the virus and disease. Hepatology 2009;49:S13-21.

30. Manns MP, Buti M, Gane E, Pawlotsky JM, Razavi H, Terrault N, et al. Hepatitis C virus infection. Nat Rev Dis Primers 2017;3:17006.

31. Denner J. Hepatitis E virus (HEV)-The Future. Viruses 2019;11:251.

32. Velavan TP, Pallerla SR, Johne R, Todt D, Steinmann E, Schenmer M, et al., Hepatitis E: An update on One Health and clinical medicine. Liver Int 2021;41:1462-1473.

33. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology 2012;142:1264-1273.

34. Alavian SM and Alavian SH. Hepatitis D virus infection; Iran, Middle East and Central Asia. Hepat Mon 2005; 5: 137.

35. Shafei, M. and S.M. Alavian. Autoimmune hepatitis in Iran: what we know, what we don’t know and requirements for better management. Hepat Mon 2012; 12:73-6.

36. Rust C and Beuers U. Overlap syndromes among autoimmune liver diseases. World J Gastroenterol 2008;14:3368-73.

37. Vergani D, Longhi MS, Bogdanos DP, Ma Y, Mieli-Vergani G. Autoimmune hepatitis. Semin Immunopathol 2009;31:421-35.

38. Courvalin, JC and Worman HJ. Nuclear envelope protein autoantibodies in primary biliary cirrhosis. Semin Liver Dis 1997;17:79-90.

39. Hov JR, Boberg KM, Karlsen TH. Autoantibodies in primary sclerosing cholangitis. World J Gastroenterol 2008;14:3781-91.

40. Zhang W, Rho JH, Roehr HL, Wang JY. A comprehensive autoantigen-ome of autoimmune liver diseases identified from dermatan sulfate affinity enrichment of liver tissue proteins. BMC Immunol 2019;20:21.

41. De Boer YS, van Gerven NM, Zwiers A, Verwer BJ, van Hoek B, van Erpecum KJ, et al. Genome-wide association study identifies variants associated with autoimmune hepatitis type 1. Gastroenterology 2014;147:443-52.e5.

42. Czaja AJ, Donaldson PT. Genetic susceptibilities for immune expression and liver cell injury in autoimmune hepatitis. Immunol Rev 2000;174:250-9.

43. Elfaramawy AA, Elhossiny RM, Abbas AA, Aziz HM. HLA-DRB1 as a risk factor in children with autoimmune hepatitis and its relation to hepatitis A infection. Ital J Pediatr 2010;36:73.

44. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, et al. Polyclonal T-cell responses to cytochrome P450 IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology 2006;130:868-82.

45. Mella JG, Roschmann E, Maier KP, Volk BA. Association of primary biliary cirrhosis with the allele HLA-DRB1* 0301 in a German population. Hepatology 1995;21:398-402.

46. Donaldson PT, Baragiotta A, Heneghan MA, Floreani A, Venturi C, Underhill JA, et al. HLA class II alleles, genotypes, haplotypes, and amino acids in primary biliary cirrhosis: a large-scale study. Hepatology 2006;44:667-74.

47. Inverizzo P, Ransoms M, Raychaudhuri S, Kosoy R, Lleo A, Shigeta R, et al., Classical HLA-DRB1 and DPB1 alleles account for HLA associations with primary biliary cirrhosis. Genes Immun 2012;13:461-8.

48. Onishi S, Sakamaki T, Maeda T, Iwamura S, Tornita A, Saibara T, et al., DNA typing of HLA class II genes; DRB1*0803 increases the susceptibility of Japanese to primary biliary cirrhosis. J Hepatol 1994;21:1053-60.
Non-coding RNAs as potential diagnostic biomarkers in liver diseases

48. Tanaka A, Leung PSC, Gershwin ME. The genetics and epigenetics of primary biliary cholangitis. Clin Liver Dis 2018;22:443-455.

49. Folserra T, Melum E, Rausch P, Juran BD, Ellinghaus E, Shiryaev A, et al. Extended analysis of a genome-wide association study in primary sclerosing cholangitis detects multiple novel risk loci. J Hepatol 2012;57:366-75.

50. Liu JZ, Hov JR, Folserra T, Ellinghaus E, Rushbrook SM, Doncheva NT, et al. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nat Genet 2013;45:670-5.

51. Ellinghaus D, Jostins L, Spain SL, Cortes A, Bethune J, Han B, et al. Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 2016;48:510-8.

52. Loosen SH, Schueller F, Trautwein C, Roy S, Roderburg C, et al. Role of circulating microRNAs in liver diseases. J Hepatol 2017;67:856-94.

53. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011;9:524-530.e1.

54. Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA, et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011;141:1249-53.

55. Moon AM, Singal AG, Tapper EB. Tapper, Contemporary epidemiology of chronic liver disease and cirrhosis. Clin Gastroenterol Hepatol 2020;18:2650-2666.

56. Leite NC, Villela-Nogueira CA, Cardoso CR, Salles GF. Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment. World J Gastroenterol 2014;20:8377-92.

57. insulin resistance in nonalcoholic fatty liver disease. Insulin resistance in nonalcoholic fatty liver disease. Curr Pharm Des 2010;16:1941-51.

58. Lazo M, Hemaez R, Eberhardt MS, Bonekamp S, Kamei I, Gullar E, et al. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988–1994. Am J Epidemiol 2013;178:38-45.

59. Ekstedt M, Franzen LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-73.

60. Sung KC, Wild SH, Byrne CD. Resolution of fatty liver and risk of incident diabetes. J Clin Endocrinol Metab 2013;98:3637-43.

61. Parise ER. Nonalcoholic fatty liver disease (NAFLD), more than a liver disease. Arq Gastroenterol 2019;56:243-245.

62. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep 2016;6:33386.

63. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. Journal of Hepatology, J Hepatol 2016;65:589-600.

64. Yu AS, Keeffe EB. Nonalcoholic fatty liver disease. Rev Gastroenterol Disord 2002;2:11-9.

65. Krentz AJ, Bedossa P. Role of Tissue Biopsy in Drug Development for Nonalcoholic Fatty Liver Disease and Other Metabolic Disorders. In: Krentz A, Weyer C, Hompesch M, Eds. Translational Research Methods in Diabetes, Obesity, and Nonalcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2019, p.245-274.

66. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015;313:2263-73.

67. Hassan K, Bhalla V, El Regal ME, A-Kader HH. Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J Gastroenterol 2014;20:12082-101.

68. Hagström H, Nasr P, Ekstedt M, Hammar U, Stil P, Hultcrantz R, et al. Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. J Hepatol 2017;67:1265-1273.

69. Cortez-Pinto H and Camilo ME. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Pract Res Clin Gastroenterol 2004;18:1089-104.

70. Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014;20:7312-24.

71. Khatun M and Ray BB. Mechanisms Underlying Hepatitis C Virus-Associated Hepatic Fibrosis. Cells 2019;8:1249.

72. Elsharkawy AM, Oakley F, Mann DA. The role and regulation of hepatic stellate cell apoptosis in reversal of liver fibrosis. Apoptosis 2005;10:927-39.

73. Kolios G, Valatas V, Kouromalis E. Role of Kupffer cells in the pathogenesis of liver disease. World J Gastroenterol 2006;12:7413-20.

74. Hara M, Kono H, Funuya S, Hirayama K, Tsuichiya M, Fujii H. Interleukin-17A plays a pivotal role in cholestatic liver fibrosis in mice. J Surg Res 2013;183:574-82.

75. Chou WY, Lu CN, Lee TH, Wu CL, Hung KS, Concejero AM, et al. Electroporative interleukin-10 gene transfer ameliorates carbon tetrachloride-induced murine liver fibrosis by MMP and TIMP modulation 1. Acta Pharmacol Sin 2006;27:469-76.

76. Zeng QL, Feng GH, Zhang JY, Chen Y, Yang B, Huang HH, et al., Risk factors for liver-related mortality in chronic hepatitis C patients: a deceased case-living control study. World J Gastroenterol 2014;20:5519-26.

77. Wiegand J and Berg T. The etiology, diagnosis and prevention of liver cirrhosis: part 1 of a series on liver cirrhosis. Dtsch Arztebl Int 2013;110:85-91.

78. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer Incidence and Mortality Worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.

79. El-Serag HB and Rudolph KL. Rudolph, Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.

80. Sanjay AJ, Yoon SK, Lencioni R. The etiology of hepatocellular carcinoma and consequences for treatment. Oncologist 2010;15 Suppl 4:14-22.
81. Udompap P, Kim D, Kim WR. Current and future burden of chronic nonmalignant liver disease. Clin Gastroenterol Hepatol 2015;13:2031-41.
82. Xu Y, Xiao A, Yang J, Zhang Z, Zhang G. Assessment of lipiodol deposition and residual cancer for hepatocellular carcinoma after transcatheter arterial chemoembolization via iodine-based material decomposition images with spectral computed tomography imaging: a preliminary study. Iran J Radiol 2015;12:e26009.
83. Juli R, Sefidbakhsh S, Kazemi K. Comparison of the accuracy of DWI and ultrasonography in screening hepatocellular carcinoma in patients with chronic liver disease. Iran J Radiol 2015;12:e12708.
84. Hemmati H, Karimian M, Moradi H, Farid Marandi K, Haghdoost A. Endovascular treatment of a huge hepatic artery aneurysm by coil embolization method: a case report. Iran J Radiol 2015;12:e5200.
85. Alavian SM and Haghbin H. Relative importance of hepatitis B and C viruses in hepatocellular carcinoma in EMRO countries and the Middle East: a systematic review. Hepat Mon 2016;16:e35106.
86. Rezaee R, Aghcheli B, Poorathamasebi V, Qorbani M, Alavian SM, Jazayeri SM. Prevalence of national responsiveness to HBV vaccine after 22 years of Iranian expanded program on immunization (EPI): a systematic review and meta-analysis study. Hepat Mon 2015;15:e23618.
87. Alavian SM. Hepatocellular Carcinoma is an Emerging Issue Now in Iran. Iran J Radiol 2017;14:e64371.
88. La Fauci V, Risò R, Facciò A, Ceccio C, Lo Giudice D, Calimeri S. Response to anti-HBV vaccine and 10-year follow-up of antibody levels in healthcare workers. Public Health 2016;139:198-202.
89. El-Serag HB and Mason AC. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000;160:3227-30.
90. Montella M, Crispo A, Giudice A. HCC, diet and metabolic factors: Diet and HCC. Hepat Mon 2011;11:159-62.
91. Schuppan D and Afdhal NH. Liver cirrhosis. Lancet 2008;371:838-51.
92. Petrick A, Benotti P, Wood GC, Still CD, Strodel WE, Gabrielsen J, et al. Utility of Ultrasound, Transaminases, and Visual Inspection to Assess Nonalcoholic Fatty Liver Disease in Bariatric Surgery Patients. Obes Surg 2015;25:2368-75.
93. Sumida Y, Nakajima A, Itoh Y. Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014;20:475-85.
94. Giannini EG, Testa R, Savarino V. Liver enzyme alteration: a guide for clinicians. CMAJ 2005;172:367-79.
95. Hamm HW, Wan S, Myers RE, Hann RS, Xing J, Chen B, et al. Comprehensive analysis of common serum liver enzymes as prospective predictors of hepatocellular carcinoma in HBV patients. PLoS One 2012;7:e47687.
96. Hall P and Cash J. What is the real function of the liver 'function' tests? Ulster Med J 2012; 81:30-6.
97. Lee JS. Albumin for end-stage liver disease. Korean J Intern Med 2012;27:13-9.
98. Contreras-Zentella ML and Hernández-Muñoz R. Is Liver Enzyme Release Really Associated with Cell Necrosis Induced by Oxidant Stress? Oxid Med Cell Longev 2016;2016:3529149.
99. Ling H, Fabbri M, Calin GA. MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 2013;12:847-65.
100. Ruan K, Fang X, Ouyang G. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009;285:116-26.
101. Lamontagne J, Steel LF, Bouchard MJ. Bouchard, Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases. World J Gastroenterol 2015;21:7375-99.
102. Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans 2008;36:1224-31.
103. Cui Q, Yu Z, Pan Y, Purisma EO, Wang E. MicroRNAs preferentially target the genes with high transcriptional regulation complexity. Biochem Biophys Res Commun 2007;352:733-8.
104. Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel) 2012;12:3359-69.
105. Fadhil RS, Nair RG, Nikolarakos D, Wei MQ. Next generation sequencing identifies novel diagnostic biomarkers for head and neck cancers. Oral Cancer 2019;3:69-78.
106. Moxon S, Jing R, Szitgya G, Schwach F, Rusholme Pilcher RL, Moulton V, et al. Deep sequencing of tomato short RNAs identifies microRNAs targeting genes involved in fruit ripening. Genome Res 2008;18:1602-9.
107. Musaddaq G, Shahzad N, Ashraf MA, Arshad ML. Circulating liver-specific microRNAs as noninvasive diagnostic biomarkers of hepatic diseases in human. Biomarkers 2019;24:103-109.
108. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev 2015;81:75-93.
109. Singh R, Ramasubramanian B, Kanji S, Chakraborty AR, Haque SJ, Chakraborti A. Circulating microRNAs in cancer: Hope or hype? Cancer Lett 2016;381:113-21.
110. Wang B, Howel P, Bruheim S, Ju J, Owen LB, Fodstad O, et al. Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array. PLoS One 2011;6:e17167.
111. Jiang Q, Wang Y, Hao Y, Juan L, Teng M, Zhang X, et al. miR2Disease: a manually curated database for microRNA targets, and signaling molecules. Nucleic Acids Res 2009;37:D98-104.
112. Sikand K, Slane SD, Shukla GC. Intrinsic expression of host genes and intronic miRNAs in prostate carcinoma cells. Cancer Cell Int 2009:9:21.
113. Shalaby T, Fiaschetti G, Baumgartner M, Grotzer MA. MicroRNA signatures as biomarkers and therapeutic target for CNS embryonal tumors: the pros and the cons Int J Mol Sci 2014;15:21554-86.
114. Zhang H, Li QY, Guo ZZ, Guan Y, Du Y, Hu YY, Liu P, et al. Serum levels of microRNAs can specifically predict liver injury of chronic hepatitis B. World J Gastroenterol 2012;18:5188-96.
115. Gui J, Tian Y, Wen X, Zhang W, Zhang P, Gao J, et al. Serum microRNA characterization identifies miR-885-5p as a
potential marker for detecting liver pathologies. Clin Sci (Lond) 2011;120:183-93.

116. Liu N, Zhang J, Jiao T, Li Z, Peng J, Cui Z, et al. Hepatitis B Virus Inhibits Apoptosis of Hepatoma Cells by Sponging the MicroRNA 15a/16 Cluster. J Virol 2013;87:13370-8.

117. Mizuno R, Kawada K, Sakai Y. The molecular basis and therapeutic potential of Let-7 MicroRNAs against colorectal cancer. Can J Gastroenterol Hepatol. 2018;2018:5769591.

118. Sarkar N and Chakravarty R. Hepatitis B virus infection, microRNAs and liver disease. Int J Mol Sci 2015;16:17746-62.

119. Tiraki D. MicroRNAs and Their Role in Viral Infection. In: Bramhachari PV, Ed. Dynamics of Immune Activation in Viral Diseases. Berlin: Springer; 2020. P.167.

120. Zhang S, Ouyang X, Jiang X, Gu D, Lin Y, Kong SK, Xie W. Dysregulated serum microRNA expression profile and potential biomarkers in hepatitis C virus-infected patients. Int J Med Sci 2015;12:590-8.

121. Rottiers V, Niää AM. MicroRNAs in metabolism and metabolic disorders. Nat Rev Mol Cell Biol 2012;13:239-50.

122. Cermelli S, Ruggieri A, Marrero JA, Iannou GN, Beretta L. Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease. PLoS One 2011;6:e23937.

123. Becker PP, Rau M, Schmitt J, Malsch C, Hammer C, Bantel H, et al. Performance of serum microRNAs-122,-192 and -21 as biomarkers in patients with non-alcoholic steatohepatitis. PLoS One 2015;10:e0142661.

124. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledenesma M, et al. Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Gut 2015;64:800-12.

125. Yamada H, Suzuki K, Ichino N, Ando Y, Sawada A, Osakabe K, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta 2013;424:99-103.

126. He Y, Huang C, Lin X, Li J. MicroRNA-29 family, a crucial therapeutic target for fibrosis diseases. Biochimie. 2013;95:1355-9.

127. López-Riera M, Conde I, Quintas G, Pedrola L, Zaragoza Á, Perez-Rojas J, et al. Non-invasive prediction of NAFLD severity: a comprehensive, independent validation of previously postulated serum microRNA biomarkers. Sci Rep 2018;8:10606.

128. Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, et al. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem 2006;99:671-8.

129. Amir KS, Elmawgoud Atia HA, Elazem Elbnhawy RA, Ezzat WM. Early diagnostic evaluation of miR-122 and miR-224 as biomarkers for hepatocellular carcinoma. Genes Dis 2017;4:215-21.

130. Varnholt H. The role of microRNAs in primary liver cancer. Ann Hepatol 2008;7:104-13.

131. Leung WK, Wong N. MicroRNAs in Human Hepatocellular Carcinoma. In: Qiao L, Ed. Molecular Aspects of Hepatocellular Carcinoma. Al Sharjah, United Arab Emirates: Bentham Science Publishers; 2012. P.56.

132. Song J, Ouyang Y, Che J, Li X, Zhao Y, Yang K, et al. Potential value of miR-221/222 as diagnostic, prognostic, and therapeutic biomarkers for diseases. Front Immunol 2017;8:56.

133. Zhang L, Li C, Fu L, Yu Z, Xu G, Zhou J, et al. Diagnostic value of circulating miRNA-122 for hepatitis B virus and/or hepatitis C virus-associated chronic viral hepatitis. Peer J 2022;10:e12759.

134. Xu P, Guo A, Xu J, Yao J, Chen H, Wang F, et al. Evaluation of a combinational use of serum microRNAs as biomarkers for liver diseases. Clin Res Hepatol Gastroenterol 2017;41:254-261.

135. Ghaempoor M, Arefian E, Mohebbi SR, Shanaki M, Kazerooni F, Hatami B. Circulating miR-625 as an Emerging Biomarker for Liver Cirrhosis. Clin Lab 2019;65.

136. Fründt T, Krause L, Hessey E, Steinbach B, Köhler D, von Felden J, et al. Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. Cancers (Basel) 2021;13:2484.

137. Afshari A, Yaghobi R, Karimi MH, Mowla J, et al. Alterations in MicroRNA gene expression profile in liver transplant patients with hepatocellular carcinoma. BMC Gastroenterol 2021;21:262.

138. Zhang X, Mens MMJ, Abozaid YJ, Bos D, Darwish Murad S, de Knecht RJ, et al. Circulatory microRNAs as potential biomarkers for fatty liver disease: the Rotterdam study. Aliment Pharmacol Ther 2021;53:432-442.

139. Migita K, Komori A, Kozaru H, Jiuchi Y, Nakamura M, Yasunami M, et al. Circulating microRNA profiles in patients with type-1 autoimmune hepatitis. PLoS One 2015;10:e0136908.

140. Jia HY, Chen F, Chen JZ, Wu SS, Wang J, Cao QY, et al. MicroRNA expression profiles related to early stage marine concanavalin A-induced hepatitis. Cell Physiol Biochem 2014;33:1933-44.

141. Song G, Jia H, Xu H, Liu W, Zhu H, Li S, et al. Studying the association of micro RNA-210 level with chronic hepatitis B progression. J Viral Hepat 2014;21:272-80.

142. Sakamoto T, Morishita A, Nomura T, Tan T, Miyoshi H, Yoneyama H, et al. Identification of microRNA profiles associated with refractory primary biliary cirrhosis. Mol Med Rep 2016;14:3350-6.

143. Padgett KA, Lan RY, Leung PC, Lleo A, Dawson K, Pfeiff J, et al. Primary biliary cirrhosis is associated with altered hepatic microRNA expression. J Autoimmun 2009;32:246-53.

144. Qin B, Huang F, Liang Y, Yang Z, Zhong R, et al. Analysis of altered microRNA expression profiles in peripheral blood mononuclear cells from patients with primary biliary cirrhosis. J Gastroenterol Hepatol 2013;28:543-50.

145. Wang X, Wen X, Zhou J, Qi Y, Wu R, Wang Y, et al. MicroRNA-223 and microRNA-21 in peripheral blood B cells associated with progression of primary biliary cholangitis patients. PLoS One 2017;12:e0184292.

146. Tan Y, Pan T, Ye Y, Ge G, Chen L, Wen D, et al. Serum microRNAs as potential biomarkers of primary biliary cirrhosis. PLoS One 2014;9:e11424.

147. Ninomiya M, Kondo Y, Funayama R, Nagashima T, Kogure T, Kakazu E, et al. Distinct microRNAs expression profile in
primary biliary cirrhosis and evaluation of miR 505-3p and miR197-3p as novel biomarkers. PLoS One 2013;8:e60686.

148. Tomiyama T, Yang GX, Zhao M, Zhang W, Tanaka H, Wang J, et al. The modulation of co-stimulatory molecules by circulating exosomes in primary biliary cirrhosis. Cell Mol Immunol 2017;14:276-284.

149. Bernuzzi F, Marabita F, Lleo A, Carbone M, Mirolo M, Marziani M, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma. Clin Exp Immunol 2016;185:61-71.

150. Voigtlander T, Gupta SK, Thum S, Fendrich J, Manns MP, Lankisch TO, et al. MicroRNAs in serum and bile of patients with primary sclerosing cholangitis and/or cholangiocarcinoma. PLoS One 2015;10:e0139305.

151. Friedrich K, Baumann C, Wannhoff A, Rupp C, Mehrabi A, Weiss KH, et al. Serum miRNA-122 is an independent biomarker of survival in patients with primary sclerosing cholangitis. J Gastrointestin Liver Dis 2018;27:145-50.

152. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 2002;99:15524-9.

153. Iorio MV, Ferracin M, Liu CG, Veronese A, Spizzo R, Sabbioni S, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res 2005;65:7065-70.

154. Cimmino A, Calin GA, Fabbrri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 2005;102:13944-9.

155. Johnson SM, Groshans H, Shingara J, Byrom M, Jarvis R, Cheng A, et al. RAS is regulated by the let-7 microRNA family. Cell 2005;120:363-47.

156. Hébert SS, Horré K, Nicolai L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of micro-RNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/ -secretase expressionPNAS. Proc Natl Acad Sci U S A 2008;105:6415-20.

157. Gehrke S, Imai Y, Sokol N, Lu B. Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression. Nature 2010;466:637-41.

158. Alisi A, Da Sacco L, Bruscalupi G, Fiemonet F, Panera N, De Vito R, et al. Mirrnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Lab Invest 2011;91:283-93.

159. Junker A, Krumholz M, Eisele S, Mohan H, Augstein F, Bittner R, et al. MicroRNA profiling of multiple sclerosis lesions identifies modulators of the regulatory protein CD47. Brain 2009;132:3342-52.

160. Trajkovski M, Hausser J, Soutschek J, Bhat B, Akin A, Zavolan M, et al. MicroRNAs 103 and 107 regulate insulin sensitivity. Nature 2011;474:649-53.

161. Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarow P, et al. Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA. Science 2005;309:1577-81.

162. Lanford RE, Hildebrandt-Eriksen ES, Petri A, Persson R, Lindow M, Munk ME, et al. Therapeutic Silencing of MicroRNA-122 in Primates with Chronic Hepatitis C Virus Infection. Science 2010;327:198-201.

163. Zhang Y, Wei W, Cheng N, Wang K, Li B, Jiang X, et al. Hepatitis C Virus-Induced Up-Regulation of MicroRNA-155 Promotes Hepatocarcinogenesis by Activating Wnt Signaling. Hepatology 2012;56:1631-40.

164. Zali N, Mohebbi SR, Esteghamat S, Chiani M, Haghighi MM, Hosseini-Asl SM, et al. Prevalence of ATP7B Gene Mutations in Iranian Patients with Wilson Disease. Hepat Mon 2011;11:890-4.

165. Esteghamat F, Noorinayer B, Sanati MH, Hekmatdoost A, Zafarghandi M, Shalmani HM, et al. C77G mutation in protein tyrosine phosphatase CD45 gene and autoimmune hepatitis. Hepatol Res 2005;32:154-7.

166. Mohebbi SR, Amini-Bavil-Olyae S, Zali N, Noorinayer B, Derakhshan F, Chiani M, et al. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect 2008;14:858-66.

167. Amini-Bavil-Olyae S, Herbers U, Mohebbi SR, Sabahi F, Zali MR, Laedde T, et al. Prevalence, viral replication efficiency and antiviral drug susceptibility of rrtQ215 polymerase mutations within the hepatitis B virus genome. J Hepatol 2009;51:647-54.

168. Mohebbi SR, Amini-Bavil-Olyae S, Zali N, Damavand B, Azimzadeh P, Derakhshan F, et al. Characterization of hepatitis B virus genome variability in Iranian patients with chronic infection, a nationwide study. J Med Virol 2012;84:414-23.

169. Salehi Moghadam F, Mohebbi SR, Hosseini SM, Romani S, Mirtalebi H, Azimzadeh P, et al. Phylogenetic analysis of hepatitis C virus strains and risk factors associated with infection and viral subtypes among Iranian patients. J Med Virol 2014;86:1342-9.

170. Araujo NM, Teles SA, Spitz N. Comprehensive Analysis of Clinically Significant Hepatitis B Virus Mutations in Relation to Genotype, Subgenotype and Geographic Region. Front Microbiol 2020;11:616023.

171. Liang YJ, Teng W, Chen CL, Sun CP, Teng RD, Huang YH, et al. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development. Hepatology 2021;74:641-655.